Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Status:
RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma.
The name of the study drug involved in this study is:
-Azenosertib (a type of Wee1 inhibitor)